US Broker Ratings

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a Promising 166% Upside Potential

Mineralys Therapeutics, Inc. (MLYS) is emerging as a noteworthy player in the biotechnology sector, with a particular focus on addressing diseases driven by dysregulated aldosterone. This clinical-stage biopharmaceutical company is..

Innoviva, Inc. (INVA) Stock Analysis: Unpacking a Potential 117% Upside in the Biotech Sector

Innoviva, Inc. (NASDAQ: INVA) is gaining attention in the biotech industry for its promising growth prospects and strategic partnerships, despite recording a recent dip in its stock price. With a..

agilon health, inc. (AGL) Investor Outlook: Exploring an 80% Potential Upside in Healthcare

For investors with an eye on the healthcare sector, agilon health, inc. (AGL) presents a fascinating, albeit complex, opportunity. With a current market cap of $823.76 million and a share..

Evotec SE (EVO) Stock Analysis: Unlocking the Potential with a 40% Upside

Evotec SE (EVO), with its roots deeply embedded in Germany’s healthcare sector, has emerged as a significant player in the drug discovery and development landscape. The company operates on a..

Mesoblast Limited (MESO): Investor Outlook on a 69.49% Potential Upside in the Biotech Sector

Mesoblast Limited (NASDAQ: MESO), a pioneering firm in the biotechnology sector, is capturing investor attention with a potential upside of 69.49% based on analyst target price forecasts. Specializing in regenerative..

Aveanna Healthcare Holdings Inc (AVAH) Stock Analysis: Unpacking a Potential 45% Upside for Investors

Aveanna Healthcare Holdings Inc (NASDAQ: AVAH), a key player in the healthcare sector, is carving out a significant niche with its diversified home care platform in the United States. With..

Mirum Pharmaceuticals (MIRM) Stock Analysis: Unpacking a 33% Potential Upside in the Biotechnology Sector

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has captured investor attention with its promising strides in the biopharmaceutical landscape, particularly in developing therapies for rare and debilitating diseases. With a market cap..

Dyne Therapeutics, Inc. (DYN): Biotech Stock with a 325% Upside Potential

Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage biotechnology firm, has been making waves in the healthcare sector with its cutting-edge approach to treating neuromuscular diseases. Headquartered in Waltham, Massachusetts, Dyne..

Harrow, Inc. (HROW) Stock Analysis: Eyeing a 70% Upside with Strong Buy Ratings

Harrow, Inc. (NASDAQ: HROW) is drawing significant attention from investors with its promising growth prospects in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. Headquartered in..

LifeStance Health Group (LFST): Investor Outlook Highlights Over 100% Potential Upside

LifeStance Health Group, Inc. (NASDAQ: LFST), a key player in the healthcare sector’s medical care facilities industry, is attracting investor attention with its significant growth potential. With a market capitalization..

Kestra Medical Technologies (KMTS): An Investor’s Insight into Potential 62.63% Upside

Investors eyeing the healthcare sector might find Kestra Medical Technologies, Ltd. (KMTS) an intriguing opportunity, especially with the potential for a significant 62.63% upside based on current analyst ratings. This..

Immunocore Holdings plc (IMCR) Stock Report: Unveiling an 83.99% Potential Upside in the Biotech Arena

Immunocore Holdings plc (NASDAQ: IMCR) is attracting investor attention with its robust pipeline in the biotechnology sector, particularly in immunotherapy for cancer and infectious diseases. As a UK-based biotech company,..

Establishment Labs Holdings Inc (ESTA) Stock Analysis: A 32% Upside Potential Makes This Healthcare Innovator a Lucrative Prospect

Establishment Labs Holdings Inc (NASDAQ: ESTA), a pioneering force in the medical devices sector, has been capturing attention with its innovative approach to aesthetic and reconstructive plastic surgeries. With a..

Teladoc Health, Inc. (TDOC) Stock Analysis: Evaluating the 12.65% Upside in a Challenging Market

Teladoc Health, Inc. (NASDAQ: TDOC) is a notable player in the healthcare sector, specifically within health information services. With a market capitalization of $1.44 billion, the company has been at..

Denali Therapeutics (DNLI) Stock Analysis: Uncovering a Potential 136% Upside for Biotech Investors

Denali Therapeutics Inc. (NASDAQ: DNLI) stands out in the biotechnology sector with a compelling story for investors keen on the healthcare space. With a current market capitalization of $1.98 billion,..

Apellis Pharmaceuticals (APLS) Stock Analysis: 89.87% Potential Upside Sparks Investor Interest

Investors eyeing opportunities in the healthcare sector might want to pay close attention to Apellis Pharmaceuticals, Inc. (NASDAQ: APLS). Known for its focus on developing innovative therapies for diseases with..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a Potential 22.64% Upside with Robust Analyst Support

Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a distinguished player within the biotechnology sector, has been attracting considerable attention from investors, particularly due to its promising drug pipeline and a substantial potential..

Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech Venture with a 203.58% Potential Upside

Vera Therapeutics, Inc. (NASDAQ: VERA), a promising player in the biotechnology sector, is making waves with its innovative approach to tackling serious immunological diseases. Headquartered in Brisbane, California, this clinical-stage..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Eye-Catching Growth and a 73.65% Upside Potential

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a pioneering entity in the biopharmaceutical sector, is drawing significant attention in the healthcare industry. Headquartered in Irvine, California, this company is dedicated to the..

Pediatrix Medical Group, Inc. (MD) Stock Analysis: Exploring a 35% Potential Upside

Pediatrix Medical Group, Inc. (NYSE: MD), a prominent player in the healthcare sector, is catching the attention of investors with its significant potential upside of 35.30%, as indicated by analyst..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds